Allergan Inc. (AGN): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Allergan ( AGN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole was unchanged today. By the end of trading, Allergan fell $1.81 (-1.5%) to $120.53 on average volume. Throughout the day, 3,557,525 shares of Allergan exchanged hands as compared to its average daily volume of 2,517,000 shares. The stock ranged in price between $120.22-$122.50 after having opened the day at $121.76 as compared to the previous trading day's close of $122.34. Other companies within the Drugs industry that declined today were: Advaxis Incorporated ( ADXS), down 24.8%, Heat Biologics ( HTBX), down 9.8%, Egalet ( EGLT), down 9.4% and Endocyte ( ECYT), down 8.3%.

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $37.2 billion and is part of the health care sector. Shares are up 10.1% year to date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Allergan a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, Northwest Biotherapeutics ( NWBO), up 15.1%, Genvec ( GNVC), up 13.7%, Inovio Pharmaceuticals ( INO), up 12.7% and MEI Pharma ( MEIP), up 12.1% , were all gainers within the drugs industry with Amgen ( AMGN) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Elizabeth Warren Slams Wells Fargo, Equifax: Cramer's Top Takeaways

Centene: Cramer's Top Takeaways

The Pitney Bowes Transformation: Cramer's Top Takeaways

Healthcare Trust of America, Marathon Petroleum: 'Mad Money' Lightning Round

How Long Can This Rally Run?: Cramer's 'Mad Money' Recap (Monday 9/19/17)